Chardan Capital Maintains Buy on Intellia Therapeutics, Lowers Price Target to $26

Intellia Therapeutics, Inc. -5.55%

Intellia Therapeutics, Inc.

NTLA

9.02

-5.55%

Chardan Capital analyst Geulah Livshits maintains Intellia Therapeutics (NASDAQ: NTLA) with a Buy and lowers the price target from $48 to $26.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via